CLSA Reiterates Outperform (2) Rating on Novartis (NOVN:SW) (NVS)

September 9, 2026 2:39 AM

CLSA analyst David Dong reiterated an Outperform (2) rating and CHF135.00 price target on Novartis (NOVN:SW) (NYSE: NVS).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found